In today’s episode, we dive into the wonders of T-cell immunology technology and how it impacts early treatment interventions with long-time drug developer Dr. Nigel McCracken. As the Chief Operating Officer of Virax Biolabs, Dr. McCracken has more than 25 years of research and development experience in this diverse field – including oncology and infectious disease…
Virax Biolabs is committed to revolutionizing global health by accelerating the development of more effective vaccines. How do they achieve this? By harnessing cutting-edge diagnostics to power a groundbreaking T-cell immunology platform, enabling early detection of post-viral syndromes and conditions linked to chronic inflammation and T-cell exhaustion.
Before joining Virax, Dr. McCracken served as Chief Scientific Officer at BerGenBio ASA, where he led the development of companion diagnostics and assay strategies. Prior to that, he was COO at NuCana PLC, a clinical-stage biopharmaceutical company dedicated to improving cancer treatment outcomes. In this role, he oversaw business operations, research and development, and the execution of corporate strategy.
Tune in now to learn about:
- The importance of early diagnosis when it comes to immune system dysfunction.
- How the complementary system interacts with the immune system.
- The typical role that T-cells play in infections.
- Why chronic health problems are on the rise, and what this could mean for the future of healthcare.
You can follow along with Dr. McCracken’s work at Virax Biolabs here!
Episode also available on Apple Podcasts: https://apple.co/30PvU9C
Upgrade Your Wallet Game with Ekster!
Get the sleek, smart wallet you deserve—and save while you’re at it! Use coupon code FINDINGGENIUS at checkout or shop now with this exclusive link: ekster.com?sca_ref=4822922.DtoeXHFUmQ5 Smarter, slimmer, better. Don’t miss out!
